Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.
Data from the following clinical trials are discussed:
P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor degrader (SERD), combined with palbociclib [Ibrance] in postmenopausal women with ER+/HER2 advanced breast cancer
GS2 -02: Elacestrant, an oral selective estrogen receptor degrader (SERD) vs investigator's choice of endocrine monotherapy for ER+/HER2 advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC estrogen receptor degrader, in ER+/HER2 locally advanced or metastatic breast cancer